A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

Clinical trial NCT05268666 · UNKNOWN

Trial details

NCT number: NCT05268666
Sponsor: Jubilant Therapeutics Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Locally Advanced Solid Tumor Metastatic Solid Tumor

Start date: 2022-04-08
Primary completion: 2024-12-01
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.